Immune-mediated glomerular diseases are a major cause of end stage renal disease and are associated with significant morbidity and mortality. Since specific treatment options and biomarkers for immune-mediated glomerular diseases were largely missing, we initiated the Collaborative Research Centre 1192 which aims at bridging the translational gap between experimental studies and improved patient outcomes within a 12 year funding perspective.
Visit www.sfb1192.de